menu
    • menu
    [{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Yonghe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ablaze Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablaze Pharma \/ Yonghe Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ablaze Pharma \/ Yonghe Pharma"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2021","type":"Series A Financing","leadProduct":"225-Ac","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ablaze Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablaze Pharma \/ Vivo Capital","highestDevelopmentStatusID":"15","companyTruncated":"Ablaze Pharma \/ Vivo Capital"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ablaze Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablaze Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ablaze Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Ablaze Pharma

    Menu

    Ablaze Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Ablaze Pharma

    China arrow
    BePharma
    Not Confirmed

    Ablaze Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Can...

    Details :

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    March 31, 2023

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Ablaze Pharma

    China arrow
    BePharma
    Not Confirmed

    Ablaze Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 225-Ac

    Therapeutic Area : Oncology

    Study Phase : Undisclosed

    Sponsor : Yonghe Pharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targete...

    Details :

    Product Name : Undisclosed

    Product Type : Other Large Molecule

    Upfront Cash : Undisclosed

    December 27, 2022

    Lead Product(s) : 225-Ac

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Sponsor : Yonghe Pharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Ablaze Pharma

    China arrow
    BePharma
    Not Confirmed

    Ablaze Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 225-Ac

    Therapeutic Area : Oncology

    Study Phase : Approved FDF

    Sponsor : Vivo Capital

    Deal Size : $75.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to T...

    Details :

    Product Name : Undisclosed

    Product Type : Other Large Molecule

    Upfront Cash : Undisclosed

    November 29, 2021

    Lead Product(s) : 225-Ac

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Sponsor : Vivo Capital

    Deal Size : $75.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth